Skip to main content
PMC home page
Journal of Neurology, Neurosurgery, and Psychiatry logoLink to Journal of Neurology, Neurosurgery, and Psychiatry
. 1992 Jan;55(1):60–62. doi: 10.1136/jnnp.55.1.60

High-dose intravenous human immunoglobulin in polymyositis resistant to treatment.

S Jann 1, S Beretta 1, M Moggio 1, L Adobbati 1, G Pellegrini 1
PMCID: PMC488936  PMID: 1372349

Abstract

Two patients were treated with treatment-resistant polymyositis with intravenous immunoglobulin over four days at a dose of 0.4 g/kg/day. Clinical recovery followed within two months. Serum creatine kinase (CK) activity decreased to normal, and a clear improvement in muscle strength was observed. One patient showed neither clinical relapses nor increase in serum CK activity after 20 months. The other showed a mild increase in serum CK activity after 24 months and was successfully retreated with intravenous immunoglobulin. There were no significant adverse side effects.

Full text

PDF
60

Selected References

These references are in PubMed. This may not be the complete list of references from this article.

  1. Arsura E. L., Bick A., Brunner N. G., Namba T., Grob D. High-dose intravenous immunoglobulin in the management of myasthenia gravis. Arch Intern Med. 1986 Jul;146(7):1365–1368. [PubMed] [Google Scholar]
  2. Baron M., Small P. Polymyositis/dermatomyositis: clinical features and outcome in 22 patients. J Rheumatol. 1985 Apr;12(2):283–286. [PubMed] [Google Scholar]
  3. Bohan A., Peter J. B., Bowman R. L., Pearson C. M. Computer-assisted analysis of 153 patients with polymyositis and dermatomyositis. Medicine (Baltimore) 1977 Jul;56(4):255–286. doi: 10.1097/00005792-197707000-00001. [DOI] [PubMed] [Google Scholar]
  4. Cook D., Dalakas M., Galdi A., Biondi D., Porter H. High-dose intravenous immunoglobulin in the treatment of demyelinating neuropathy associated with monoclonal gammopathy. Neurology. 1990 Feb;40(2):212–214. doi: 10.1212/wnl.40.2.212. [DOI] [PubMed] [Google Scholar]
  5. Dwyer J. M. Intravenous therapy with gamma globulin. Adv Intern Med. 1987;32:111–135. [PubMed] [Google Scholar]
  6. Engel W. K., Lichter A. S., Galdi A. P. Polymyositis: remarkable response to total body irradiation. Lancet. 1981 Mar 21;1(8221):658–658. doi: 10.1016/s0140-6736(81)91567-1. [DOI] [PubMed] [Google Scholar]
  7. Engelhard D., Waner J. L., Kapoor N., Good R. A. Effect of intravenous immune globulin on natural killer cell activity: possible association with autoimmune neutropenia and idiopathic thrombocytopenia. J Pediatr. 1986 Jan;108(1):77–81. doi: 10.1016/s0022-3476(86)80772-7. [DOI] [PubMed] [Google Scholar]
  8. Faed J. M., Day B., Pollock M., Taylor P. K., Nukada H., Hammond-Tooke G. D. High-dose intravenous human immunoglobulin in chronic inflammatory demyelinating polyneuropathy. Neurology. 1989 Mar;39(3):422–425. doi: 10.1212/wnl.39.3.422. [DOI] [PubMed] [Google Scholar]
  9. Goei The H. S., Jacobs P., Houben H. Cyclosporine in the treatment of intractable polymyositis. Arthritis Rheum. 1985 Dec;28(12):1436–1437. doi: 10.1002/art.1780281220. [DOI] [PubMed] [Google Scholar]
  10. Henriksson K. G., Sandstedt P. Polymyositis--treatment and prognosis. A study of 107 patients. Acta Neurol Scand. 1982 Apr;65(4):280–300. doi: 10.1111/j.1600-0404.1982.tb03087.x. [DOI] [PubMed] [Google Scholar]
  11. Hubbard W. N., Walport M. J., Halnan K. E., Beaney R. P., Hughes G. R. Remission from polymyositis after total body irradiation. Br Med J (Clin Res Ed) 1982 Jun 26;284(6333):1915–1916. doi: 10.1136/bmj.284.6333.1915. [DOI] [PMC free article] [PubMed] [Google Scholar]
  12. Klinman D. M., Steinberg A. D. Idiotypy and autoimmunity. Arthritis Rheum. 1986 Jun;29(6):697–705. doi: 10.1002/art.1780290601. [DOI] [PubMed] [Google Scholar]
  13. Roifman C. M., Schaffer F. M., Wachsmuth S. E., Murphy G., Gelfand E. W. Reversal of chronic polymyositis following intravenous immune serum globulin therapy. JAMA. 1987 Jul 24;258(4):513–515. doi: 10.1001/jama.1987.03400040111034. [DOI] [PubMed] [Google Scholar]
  14. Rose A. L., Walton J. N. Polymyositis: a survey of 89 cases with particular reference to treatment and prognosis. Brain. 1966 Dec;89(4):747–768. doi: 10.1093/brain/89.4.747. [DOI] [PubMed] [Google Scholar]
  15. Tymms K. E., Webb J. Dermatopolymyositis and other connective tissue diseases: a review of 105 cases. J Rheumatol. 1985 Dec;12(6):1140–1148. [PubMed] [Google Scholar]
  16. Whitaker J. N., Engel W. K. Vascular deposits of immunoglobulin and complement in idiopathic inflammatory myopathy. N Engl J Med. 1972 Feb 17;286(7):333–338. doi: 10.1056/NEJM197202172860701. [DOI] [PubMed] [Google Scholar]
  17. Yoshioka M., Okuno T., Mikawa H. Prognosis and treatment of polymyositis with particular reference to steroid resistant patients. Arch Dis Child. 1985 Mar;60(3):236–244. doi: 10.1136/adc.60.3.236. [DOI] [PMC free article] [PubMed] [Google Scholar]
  18. Zanetti M. Idiotypic regulation of autoantibody production. Crit Rev Immunol. 1986;6(2):151–183. [PubMed] [Google Scholar]
  19. van Doorn P. A., Brand A., Strengers P. F., Meulstee J., Vermeulen M. High-dose intravenous immunoglobulin treatment in chronic inflammatory demyelinating polyneuropathy: a double-blind, placebo-controlled, crossover study. Neurology. 1990 Feb;40(2):209–212. doi: 10.1212/wnl.40.2.209. [DOI] [PubMed] [Google Scholar]

Articles from Journal of Neurology, Neurosurgery, and Psychiatry are provided here courtesy of BMJ Publishing Group

RESOURCES